KNTE News and Press, Kinnate Biopharma Inc. From 02/16/24

EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0...

2023-12-12 01:26:03 ET Summary Kinnate Biopharma is focusing on the development of a novel RAF inhibitor to overcome challenges in targeted therapy for melanoma and other BRAF-mutated cancers. The company is narrowing its near-term development to work on the RAF inhibitor exarafen...

2023-11-15 13:30:05 ET Kinnate Biopharma ( KNTE ) +47% . SciSparc  ( SPRC ) +46% . Ebix ( EBIX ) +41% . Beauty Health Company ( SKIN ) +35% . Mira Pharmaceuticals ( MIRA ) +38% . Solid Biosciences  ( SLDB ) +28% ...

2023-11-15 12:32:14 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Cormedix Inc (NASDAQ: CRMD), SciSparc Ltd (NASDAQ: SPRC), Solid Biosciences Inc (NASDAQ: SLDB), Heron ...

Kinnate Biopharma Inc. (NASDAQ: KNTE) is one today's most active stocks by volume. So far today, approximately 75,328 shares of Kinnate Biopharma Inc. have been exchanged, as compared to an average 30-day volume of 115.51k shares. Kinnate Biopharma Inc., a biopharmaceutical company, focuses on...

2023-11-15 09:50:09 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SciSparc Ltd (NASDAQ: SPRC), Chemomab Therapeutics Ltd (NASDAQ: CMMB), Cellectis SA (NASDAQ: CLLS), AstraZene...

2023-11-15 08:45:04 ET SciSparc ( SPRC ) +86% Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation. Kinnate Biopharma  ( KNTE ) +41% . Solid Biosciences  ( SLDB ) +27% gets FDA okay for clinical testing of DMD gene th...

2023-11-09 17:48:39 ET Kinnate Biopharma press release ( NASDAQ: KNTE ): Q3 GAAP EPS of -$0.65 beats by $0.04 . As of September 30, 2023, total cash, cash equivalents and investments were $180.3 million, which is expected to fund current operations into at least the se...

Reported promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 select...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...